PROBAN aims at reducing the pressure on patients and health systems with better informed decisions for the downstream healthcare choices and at decreasing the associated cost burden.
PIONEERING NON-INVASIVE DIAGNOSTIC TESTS FOR CANCER
ONTRACK Biomedical has developed an innovative method for the generation of high-affinity monoclonal antibodies. This allows the development of highly sensitive and specific immunoassays in a fast and cost-effective way and enables the quick generation of in-vitro diagnostic tests in any medical field. Our technology is particularly suitable for non-invasive tests, allowing the quantification of known and novel biomarkers in serum, blood and urine
ONTRACK Biomedical innovative method is based on the generation and selection of high-affinity monoclonal antibodies against any specific target, a process of negative selection can be used to avoid the quantification of off-target proteins.
Fast and cost-efficient
Our innovative method is not only very efficient in terms of sensitivity and specificity of the immunoassays, but it also enables the quick and cost effective development of IVDs. Thanks to its flexibility, it is now possible to provide multi-plex immunoassays quantifying, with high analytical sensitivity, multiple target biomarkers in one test.
Novel biomarkers discovery: Proban
ONTRACK Biomedical has developed a unique strategy for the discovery of novel biomarker in non-invasive biological samples. This strategy can be applied to any disease and biological material. The first application is PROBAN, which is based on the quantification of 60 novel biomarkers for the early detection of prostate cancer (Alijaj et al, Cancers 2022).